Clinical Trial Update: Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation [Phase 2]

View source ↗

Summary

A Phase 2 trial of TY-9591 in non-small cell lung cancer with EGFR activating mutation and brain or leptomeningeal metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• TY-9591 (TY-9591)

Snippet

Sponsor: TYK Medicines, Inc | Conditions: NSCLC, EGFR Activating Mutation | Phase 2 | Status: COMPLETED